High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: Impact on arterial thrombus formation

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 1024-1035

  Holy, Erik W ^a,b   Besler, Christian ^a,b   Reiner, Martin F ^a   Camici, Giovanni G ^a,b   Manz, Jasmin ^a   Beer, Jürg H ^c   Lüscher, Thomas F ^a,b   Landmesser, Ulf ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Kantonsspital Baden   (Switzerland)

Author keywords

Animal models; Arterial thrombosis; Endothelial cells; Nitric oxide; Tissue factor factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; HIGH DENSITY LIPOPROTEIN; N (G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCAVENGER RECEPTOR BI; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; 2,2'-(HYDROXYNITROSOHYDRAZONO)BIS-ETHANAMINE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITROSO DERIVATIVE; SERPINE1 PROTEIN, HUMAN; THROMBIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING; ANIMAL; AORTA; BIOSYNTHESIS; BLOOD; CAROTID ARTERY INJURY; CELL CULTURE; COMPLICATION; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; SECRETION (PROCESS);

ACUTE CORONARY SYNDROME; ADULT; AGED; ANIMALS; AORTA; BLOOD COAGULATION; CAROTID ARTERY INJURIES; CELLS, CULTURED; CORONARY DISEASE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MICE; MIDDLE AGED; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROSO COMPOUNDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; THROMBIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84908541413     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-09-0775     Document Type: Article

References (36)

1. Furie B, Furie BC. Mechanisms of Thrombus Formation. N Engl J Med 2008; 359: 938-949.
2. Holy EW, Tanner FC. Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention. Adv Pharmacol 2010; 59: 259-292.
3. Owens AP, Mackman N. Tissue factor and thrombosis: The clot starts here. hromb Haemost 2010; 104: 432-439.
4. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993; 72: 413-421.
5. Farrehi PM, Ozak KC, Carmeliet P, et al. Regulation of Arterial Thrombolysis by Plasminogen Activator Inhibitor-1 in Mice. Circulation 1998; 97: 1002-1008.
6. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
7. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
8. Raghunath PN, Tomaszewski JE, Brady ST, et al. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1432-1443.
9. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb Vasc Biol 1993; 13: 1090-1100.
10. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
11. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-1364.
12. Degoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 2011; 8: 266-277.
13. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001; 7: 853-857.
14. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120: 2095-2104.
15. Viswambharan H, Ming XF, Zhu S, et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res. 2004; 94: 918-925.
16. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010; 121: 110-122.
17. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121: 2693-2708.
18. Holy EW, Forestier M, Richter EK, et al. Dietary linolenic acid inhibits arterial thrombus formation, tissue factor expression, and platelet activation. Arterioscler Thromb Vasc Biol 2011; 31: 1772-1780.
19. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl 1): S34-42.
20. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-358.
21. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009; 302: 1993-2000.
22. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1316.
23. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J Am Med Assoc 2001; 285: 1711-1718.
24. Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19: 378-383.
25. Nofer JR, van der Giet M, Tölle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-581.
26. Spieker LE, Sudano I, Hürlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402.
27. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101: 2144-2148.
28. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18: 1771-1779.
29. Konstantinides S, Schäfer K, Thinnes T, et al. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103: 576-583.
30. Valiyaveettil M, Kar N, Ashraf MZ, et al. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor b I. Blood 2008; 111: 1962-1971.
31. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120: 2095-2104.
32. de Graaf JC, Banga JD, Moncada S, et al. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-2290.
33. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90: 1718-1725.
34. Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial antiand proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013; 127: 891-904.
35. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-756.
36. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13: 1176-1184.